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MAJOR ARTICLE

Inhaled Nitric Oxide as an Adjunctive Treatment
for Cerebral Malaria in Children: A Phase II
Randomized Open-Label Clinical Trial
Juliet Mwanga-Amumpaire,1,2,a Ryan W. Carroll,3,4,6,11,a Elisabeth Baudin,7 Elisabeth Kemigisha,1 Dorah Nampijja,2
Kenneth Mworozi,1 Data Santorino,2 Dan Nyehangane,1 Daniel I. Nathan,3 Pierre De Beaudrap,8 Jean-François Etard,7,8
Martin Feelisch,9 Bernadette O. Fernandez,9 Annie Berssenbrugge,10 David Bangsberg,4,11 Kenneth D. Bloch,3,5
Yap Boum II,1,2 and Warren M. Zapol3,11
1

Epicentre Mbarara Research Centre, and 2Mbarara University of Science and Technology, Uganda; 3Department of Anesthesia, Critical Care, and Pain
Medicine, 4Center for Global Health, 5Cardiovascular Research Center, Department of Medicine, Massachusetts General Hospital, and 6Pediatric Critical
Care Medicine, MassGen Hospital for Children, Boston, Massachusetts; 7Epicentre, Paris, France; 8UMI 233, Institut de Recherche Pour le Développement,
Université Montpellier 1, France; 9University of Southampton, United Kingdom; 10Ikaria, Clinton, New Jersey, and 11Harvard Medical School, Cambridge,
Massachusetts

Background. Children with cerebral malaria (CM) have high rates of mortality and neurologic sequelae. Nitric
oxide (NO) metabolite levels in plasma and urine are reduced in CM.
Methods. This randomized trial assessed the efﬁcacy of inhaled NO versus nitrogen (N2) as an adjunctive treatment for CM patients receiving intravenous artesunate. We hypothesized that patients treated with NO would have a
greater increase of the malaria biomarker, plasma angiopoietin-1 (Ang-1) after 48 hours of treatment.
Results. Ninety-two children with CM were randomized to receive either inhaled 80 part per million NO or N2
for 48 or more hours. Plasma Ang-1 levels increased in both treatment groups, but there was no difference between
the groups at 48 hours (P = not signiﬁcant [NS]). Plasma Ang-2 and cytokine levels (tumor necrosis factor-α, interferon-γ, interleukin [IL]-1β, IL-6, IL-10, and monocyte chemoattractant protein-1) decreased between inclusion and
48 hours in both treatment groups, but there was no difference between the groups (P = NS). Nitric oxide metabolite
levels—blood methemoglobin and plasma nitrate—increased in patients treated with NO (both P < .05). Seven patients in the N2 group and 4 patients in the NO group died. Five patients in the N2 group and 6 in the NO group had
neurological sequelae at hospital discharge.
Conclusions. Breathing NO as an adjunctive treatment for CM for a minimum of 48 hours was safe, increased
blood methemoglobin and plasma nitrate levels, but did not result in a greater increase of plasma Ang-1 levels at 48
hours.
Keywords. cerebral malaria; methemoglobin; nitric oxide; Plasmodium falciparum.

Malaria kills more than half a million people per year,
and most are children in sub-Saharan Africa [1]. Cerebral
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malaria (CM) is a catastrophic sequel of Plasmodium
falciparum malaria, with a mortality rate of approximately 20% [2], causing long-term neurological defects
in 10% to 24% of survivors [3, 4]. The most effective antiparasitic therapy is intravenous (IV) artesunate, which
reduced mortality from 21% to 18% in African children
with CM [2]. Several adjunctive therapies have been
tested, but none have proven to be effective [5].
Nitric oxide (NO) is an intercellular messenger molecule synthesized by various cell types, including vascular endothelial cells. Nitric oxide is a vasodilator and
inhibits platelet aggregation, among numerous other effects [6]. Malaria severity was correlated with reduced
levels of biochemical markers of NO production [7].
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Physiological markers of reduced NO bioavailability—reduced
brachial artery postischemic vasodilation [8, 9] and increased
pulmonary arterial pressures [10]—were correlated with
increased cell-free hemoglobin levels in patients with severe
malaria, reﬂecting the NO-scavenging property of cell-free
hemoglobin.
Angiopoietin (Ang)-1 and its antagonist Ang-2 regulate endothelial activation, and serum, plasma, or whole blood levels
have been studied as biomarkers of CM severity and disease
progression. Angiopoietin-1 levels were reduced and Ang-2 levels were elevated in pediatric CM patients compared with
healthy children [11] and uncomplicated malaria patients [12,
13]. Signiﬁcantly elevated levels of Ang-2 were found in fatal
cases of CM and severe malaria [13].
Breathing low concentrations of NO gas reduces pulmonary
arterial pressures without producing systemic hypotension in
animal models and children [14, 15], and inhaled NO has
been safely used to treat persistent pulmonary hypertension
and other pulmonary disorders [16, 17] in neonates and infants
for over 20 years [18]. In Plasmodium berghei ANKA (PbA)-infected mice (a murine CM model), breathing 40 or 80 parts per
million ( ppm) of inhaled NO [19, 20] improved survival rates,
reduced plasma inﬂammatory markers, and increased plasma
Ang-1 levels. In other studies, inhaled NO reduced cerebral
injury in murine models of stroke [21, 22] and traumatic
brain injury [23].
Based on the well established clinical safety proﬁle of inhaled
NO and its efﬁcacy in experimental models of CM, we conducted an open-label randomized trial of breathing 80 ppm NO versus nitrogen (N2) as an adjunctive therapy to IV artesunate in
pediatric CM patients in Uganda. The primary endpoint was to
compare the increase of plasma Ang-1 levels over the ﬁrst 48
hours of treatment in patients breathing either NO or N2. Nitric
oxide delivery and safety were monitored and assessed by measuring methemoglobin% (metHb%) and NO metabolites. Although
the study was too small to detect signiﬁcant changes, in-hospital
mortality, time to recovery from coma, and neurologic sequelae
for up to 6 months after discharge were also determined.
METHODS
Study Participants

We screened children aged 2 months to 12 years, weighing 5–
20 kg, at the tertiary care Mbarara Regional Referral Hospital
(MRRH) Pediatric Ward and the Holy Innocents Children’s
Hospital. We enrolled patients with a Blantyre coma score
(BCS) [24] <3/5 (for children aged <4 years) or Glasgow coma
score (GCS) <7/15 (for children aged 4–12 years), with a Plasmodium infection conﬁrmed by thick blood smear (see Supplementary Box 1 for additional inclusion and exclusion criteria).
Potential study patients were transferred to the research unit at
MRRH, and Ugandan research staff obtained informed consent
2
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from ﬁrst-degree relatives, using materials written in English
and Runyankole (the local language). See the Supplement for
the full description of the institutions and supporting companies involved.
Study Design and Randomization

This was a randomized open-label, phase II clinical trial comparing breathing air or oxygen supplemented with inhaled NO
(80 ppm [by volume] in N2) or N2 in children with CM. Nitrogen has been used as an inert gas control in other trials of
inhaled NO [25]. After consent was obtained, we randomized
patients to either study arm using off-site computer-generated
random allocation. Sealed envelopes contained the patient
treatment designation and were opened after consent and
enrollment.
Survival was deﬁned as alive at the time of hospital discharge.
Patients were examined for neurological sequelae at the time of
discharge and at follow-up neurological assessments at 1, 3, and
6 months after discharge.
Study Oversight

This study was conducted in accordance with the ethical standards of the Helsinki Declaration of the World Medical Association, and was approved by the institutional review boards of the
following institutions: Massachusetts General Hospital, Mbarara
University of Science and Technology, the Ugandan National
Council for Science and Technology, the Comité de Protection
des Personnes France, and Médecins Sans Frontières International. The US Food and Drug Administration was notiﬁed, but an
Investigational New Drug approval was not required. The Ugandan National Drug Authority approved the study. A data and
safety monitoring board was convened biannually, for a total of
3 meetings, to review the unblinded safety data based on serious
adverse events and mortality. The trial was registered under the
ClinicalTrials.gov: NCT01388842.
Study Procedures

The patient’s vital signs and coma score were assessed and
logged every 2 hours. Transcutaneous pulse oxygen saturation
(SpO2), methemoglobin (SpMET), hemoglobin levels, and
pulse rate were continuously monitored noninvasively with a
Radical 7 co-oximeter (Masimo, Irvine, CA). When elevated
transcutaneous SpMET levels were detected, blood metHb%
was measured with an Avox 4000 spectrophotometer (ITC,
Cambridge, MA) for conﬁrmation. Whole-blood hemoglobin
(g/dL) levels were measured with a Hemo Control Hemoglobin
Analyzer (EKF Diagnostics, Cardiff, UK). If the metHb% level
was 8.5% or greater, the inhaled gas dose was reduced by 50%
and then reduced by an additional 25% of the original dose if
the metHb% did not decrease below 8.5% within 1–2 hours.
Blood was sampled by venipuncture at enrollment (15 minutes before initiating study gas treatment, time 0) and at 12, 24,

48, 72, and 120 hours after commencing treatment with study
gas. Blood-based measurements included the following: hemoglobin, complete blood count, parasite smears, and plasma levels of creatinine, lactate, Ang-1 and Ang-2, cytokines (tumor
necrosis factor [TNF]-α, interferon [IFN]-γ, interleukin [IL]1β, IL-6, IL-10, and monocyte chemoattractant protein
[MCP]-1), S100b, and NO metabolites (nitrate, nitrite, N-nitrosamines [RNNO], S-nitrosothiols [RSNO]). A total of 10 mL of
blood was sampled for research analyses from each patient over
the 5-day study period. See the Supplement for a description of
speciﬁc laboratory procedures.

received treatment gas for greater than 48 hours, or if the patient
completed 120 hours of gas treatment regardless of clinical status,
the treatment gas was reduced by 50% each hour until turned off.
Concomitant Treatment

Enrolled patients received IV artesunate per protocol for at least
48 hours and up to 5 days. Patients able to take oral medications
were transitioned to a 3-day course of artemether/lumefantrine
(Coartem; Novartis Pharma, Switzerland) after 48 hours of IV
artesunate treatment (see the Supplement for additional treatments and interventions).
Study Endpoints

Gas Administration

Study gas was delivered to the patient via a nasal cannula with a
metered dosing apparatus speciﬁcally developed for investigational use (INOPulseTM, Ikaria, Inc., NJ) [25]. The gas volume,
and thus the gas dose to be delivered, was determined with a
nomogram, incorporating the child’s weight (to estimate tidal
volume) and respiratory rate (see the Supplement for further
description). Because the INOPulse was limited to 10 mL of
gas injection per breath, to avoid under-dosing NO gas we
were restricted to enrolling children weighing less than 20 kg.
Enrolled patients received study gas for a targeted minimum
of 48 hours and a maximum of 120 hours. All patients with a
SpO2 ≤ 94% were given supplemental oxygen by facemask.
If, during the course of treatment, a patient’s respiratory rate
(and therefore alveolar minute ventilation) changed, his/her INOPulse gas dose was adjusted using the nomogram. If the patient
regained full consciousness (BCS 5/5 or GCS 15/15) and had

Figure 1.

The primary study endpoint was the increase of plasma Ang-1 levels at 48 hours. The secondary laboratory endpoints included reduction in plasma Ang-2, the Ang-2/Ang-1 ratio, selected plasma
cytokine levels and creatinine, and blood lactate. The Ang-2/Ang1 ratio was calculated for each patient, and the mean of these ratios
is reported. Additional secondary endpoints included mortality
during hospitalization, time taken to recover from coma, and neurological sequelae occurring up to 6 months after discharge. We
evaluated the safety of NO delivery, and we monitored metHb%
and NO metabolites to conﬁrm inhalation and uptake of NO.
Statistical Analysis

We compared proportions with a χ² or Fisher’s exact test with
2-sided P values. We assessed data within groups using a 2tailed paired t test or Wilcoxon matched-pairs signed-rank
test, and we assessed data between groups using a Mann–
Whitney U test. Data between the N2 and NO treatment

Screening, enrollment, and randomization ﬂow diagram. Abbreviations: metHb%, percentage of methemoglobin; N2, nitrogen; NO, nitric oxide.
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Table 1. Baseline Clinical and Laboratory Data of Patients Enrolled
in the Treatment Groups*
Characteristic

N2 (N = 46)

Female sex, no. (%)
Age, month
Age <48 month, no. (%)
Age ≥48 month, no. (%)

NO (N = 46)

24 (52.2%)

19 (41.3%)

33.5 ± 22.4
36 (78.3%)

42.4 ± 23.3
29 (63.0%)

10 (21.7%)

17 (37.0%)

Weight, kg
Temperature, °C

11.6 ± 3.7
38.1 ± 1.1

12.7 ± 3.3
37.9 ± 1.3

SpO2, %

97.8 ± 4.2

98.2 ± 2.0

Blood metHb, % (N)
Heart rate, BPM

0.6 ± 0.1 (37)
147 ± 23

0.6 ± 0.1 (34)
143 ± 25

Respiratory rate, BPM
Blood pressure, mmHg
Systolic (N)

37 ± 11

38 ± 13

95 ± 11 (45)

98 ± 11 (44)

53 ± 12 (45)

55 ± 10 (44)

Blantyre coma score (N)
Glasgow coma score (N)

1.3 ± 0.7 (36)
5.6 ± 0.7 (10)

1.2 ± 0.8 (29)
5.9 ± 0.5 (17)

History of seizures prior to
admission, no. (%)

40 (87.0)

38 (82.6)

Malaria retinopathy (any finding),
no. (%)

27 (58.7)

23 (50.0)

Diastolic (N)

WBC, no. ×103/µL

13.5 ± 7.1

16.8 ± 11.4

Hematocrit, %
Hemoglobin, g/dL

23.3 ± 5.3
7.8 ± 2.1

25.9 ± 6.7
8.7 ± 2.2

Platelets, no. ×103/µL

93 ± 83

78 ± 68

Parasites, trophozoites,
Parasite no. ×103/µL (N)

61 ± 100

56 ± 130

Abbreviations: BPM, beats per minute; metHb, methemoglobin; N2, nitrogen; NO,
nitric oxide; NS, not significant; SD, standard deviation; SpO2, transcutaneous
pulse oxygen saturation; WBC, white blood cells.
* All data are mean ± SD. P = NS comparing N2 to NO.

cohorts, and within treatment cohorts at hours 0 and 48, were
compared from patients who received gas for at least 48 hours
and those for whom we had paired data. We compared survival
and time to coma recovery curves using Kaplan–Meier curves
and log-rank test (or Wilcoxon Breslow when appropriate). Statistics and graphs were generated with Stata software (Release
13, StataCorp.) and GraphPad Prism 6 (GraphPad Software,
Inc.). The level of statistical signiﬁcance was set at 0.05. All results are displayed as mean ± standard deviation (SD). The target census for the study was 92 patients (see the Supplement for
a description of how the study was powered).
RESULTS
Baseline Characteristics and Clinical Course

Between September 2011 and July 2013, 360 patients with a
clinical diagnosis of CM were screened for eligibility. Ninetytwo patients were included in the study, and their parent or
guardian gave informed consent to enter the trial. Forty-six patients were randomly assigned to each treatment group. Eight
4
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Figure 2. (A) Kaplan-Meier curves comparing survival in pediatric patients
with cerebral malaria (CM) treated with nitrogen (N2) or nitric oxide (NO).
P = not signiﬁcant (NS). (B) Kaplan-Meier curves for resolution of coma
in pediatric patients with CM, N2 vs NO; resolution of coma is deﬁned as
Blantyre coma score ≥ 3 or Glasgow coma score of ≥7; (N2 N = 39, NO
N = 41). P = NS. Abbreviations: INO, inhaled NO; metHb%, percentage of
methemoglobin.

patients enrolled in the study were not included in the perprotocol analysis: 3 patients in the N2 group and 5 patients in
the NO group (Figure 1). There was no difference in baseline
characteristics or laboratory values between enrolled NO- and
N2-treated patients (Table 1).
There was no difference in the duration of treatment with
study gas among patients treated ≥48 hours: 60.1 ± 23.3 hours
and 63.9 ± 23.9 hours for N2- and NO-treated patients, respectively (P = not signiﬁcant [NS]). For patients receiving NO, the
mean inhaled dose for the initial 48 hours of therapy was
0.55 ± 0.12 mg/kg per hour (N = 39) (Figure 2A).
Seventy-nine patients (38 N2, 41 NO) returned for examination at 1 month after discharge, 76 patients (37 N2, 39 NO)
returned at 3 months, and 75 patients (36 N2, 39 NO) returned
at 6 months. The trial ended when the ﬁnal enrolled patient
completed the 6-month follow-up visit, in February 2014.
Primary and Secondary Endpoints and Outcomes

Table 2 shows the plasma Ang-1 and Ang-2 levels and the Ang2/Ang-1 ratio at baseline (hour 0) and 48 hours later (hour 48).

Table 2.

Primary and Secondary Laboratory Outcomes*

Angiopoietins
Ang-1, pg/dL

Ang-2, pg/dL

Ang-2/Ang-1 Ratio

Interval

IL-1β, pg/mL

IL-6, pg/mL

Hour 0

2049 ± 2392

1733 ± 2485

3235 ± 3516

2837 ± 3152

Hour 0

16235 ± 16216

14440 ± 12202

5901 ± 8424

4801 ± 4831

Hour 0

19.62 ± 24.29

35.35 ± 119.10

Hour 48

7.80 ± 20.58

5.71 ± 11.35

N2 (N = 40)

NO (N = 40)

Hour 0

0.297 ± 0.495

0.311 ± 0.600

Hour 48

0.095 ± 0.410

0.008 ± 0.026

Hour 0

0.359 ± 0.631

0.508 ± 0.910

Hour 48

0.151 ± 0.649

0.024 ± 0.074

Intergroup P Value
.73

Hour 48

N2 = 0.085
NO = 0.016

.81

N2 < 0.0001
NO < 0.0001

.78

N2 < 0.0001
NO < 0.0001

.96

.41

.94

.90
N2 = 0.0005
NO < 0.0001

.99

N2 = 0.007
NO < 0.0001

.93

N2 < 0.0001
NO < 0.0001

.70

N2 < 0.0001
NO = 0.0001

.85

.74

Hour 0

84.63 ± 108.60

99.19 ± 122.30

Hour 48

8.04 ± 27.56

13.46 ± 60.56

N2 (N = 37)

NO (N = 38)

Hour 0

931.2 ± 813.7

922.7 ± 861.5

Hour 48

283.8 ± 400.4

318.8 ± 477.1

S100b
S100b, pg/mL

Intragroup P Value

NO (N = 39)

Hour 48

Cytokines
TNF-α, pg/mL

N2 (N = 42)

.88

.80

Abbreviations: Ang, angiopoietin; IL, interleukin; N2, nitrogen; NO, nitric oxide; SD, standard deviation; TNF, tumor necrosis factor.
* Plasma levels of Ang-1, Ang-2, cytokines, and S100b, as well as the ratio of plasma Ang-2 levels to plasma Ang-1 levels on enrollment and after 48 hours. All data
are mean ± SD.

There was an increase of plasma Ang-1 levels in the NO group
over 48 hours (P = .016), whereas there was no statistically signiﬁcant increase in the N2 group (P = .085). However, there was
no difference in the change from baseline of plasma Ang-1 levels
between the treatment groups. There was a signiﬁcant decrease
in plasma Ang-2 levels and the Ang-2/Ang-1 ratios over the 48
hours of treatment in both groups (P < .0001). There was no difference in (1) plasma Ang-2 or (2) the Ang-2/Ang-1 ratio between the treatment groups at either 0 or 48 hours.
In both groups, plasma TNF-α, IL-1β, and IL-6 levels were
less at 48 hours than upon enrollment (Table 2), but there
was no difference between the treatment groups at 0 or 48
hours (P = NS). Similar ﬁndings were obtained for plasma levels
of IFN-γ, IL-10, and MCP-1 (Supplementary Table 1). Plasma
levels of S100b, a biomarker of neural tissue injury [26], decreased after 48 hours in both treatment groups (Table 2),
with no difference between treatment groups (P = NS).
There was no difference in the time to clear circulating parasites between the N2 (N = 40) and NO (N = 43) treatment
groups: 42.9 ± 26.2 and 40.7 ± 26.1 hours, respectively. Moreover, there was no signiﬁcant difference in (1) the rate children
became afebrile (<38°C) or (2) the change of blood creatinine or
lactate levels over 48 hours between the gas treatment groups
(see Supplementary Table 2 for creatinine and lactate levels).

There were no clinically signiﬁcant differences in heart rate,
systolic blood pressure, or SpO2 after initiating treatment in patients receiving NO versus N2. In addition, the number of patients affected by severe adverse events (SAEs), or any adverse
events (AEs), including cardiopulmonary or respiratory complications, was similar in the 2 treatment groups.
Eleven (12.0%) of 92 enrolled CM patients died while in the
hospital (Table 3), 7 of whom were treated with N2 (15.2%) and
4 of whom were treated with NO (8.7%). Of the patients who
were living at the time of hospital discharge (39 N2, 42 NO),

Table 3.

Secondary Clinical Outcomes*
N2

NO

Died before 7 days after
enrollment

7 of 46 (15.2%)

4 of 46 (8.7%)

Survived 1 month after
discharge
Neurological sequelae
in 1-month survivors

39 of 46 (84.8%)

42 of 46 (91.3%)

5 of 39 (12.8%)

6 of 42 (14.3%)

Full recovery in 1-month
survivors

34 of 39 (87.2%)

36 of 42 (85.7%)

Abbreviations: N2, nitrogen; NO, nitric oxide; NS, not significant.
* All data are presented as number and percentage of patients in each
treatment group. P = NS comparing N2 to NO.
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Figure 3. (A) Delivered dose of nitric oxide (NO) over 120 hours (mg/kg per hour); (B) blood methemoglobin ( percentage of methemoglobin [metHb %]) in
patients treated with nitrogen (N2) and NO; (C) Plasma nitrate (μM) levels; and (D) plasma nitrite (μM) levels in patients treated with N2 or NO. *P < .001
and **P < .05, NO versus N2. All data mean ± standard deviation.

5 of the patients treated with N2 (12.8%) and 6 of the patients
treated with NO (14.3%) exhibited neurological sequelae at the
1-month follow-up visit. Neurological sequelae included ataxia,
hemiplegia, hypotonia, seizures, speech dysfunction, and/or behavioral disorders. Of the 11 patients with neurological sequelae
at the time of discharge, 3 patients (1 N2, 2 NO) resolved their
neurological sequelae by the 6-month follow-up visit. Figure 3A
shows the Kaplan-Meier survival curve for the 5 days after randomization into the study for patients treated with either N2 or
NO (P = NS). There was no difference in the rate of recovery
from coma between the NO and N2 treatment groups (P =
NS; Figure 3B), with the duration of coma of 48.1 ± 58.2
hours and 55.8 ± 50.1 hours for the N2 and NO treatment
groups, respectively.
Focusing only on those patients with evidence of malarial retinopathy (N = 27, 58.7% N2 group; N = 23, 50.0% NO group),
we observed that there was no difference in the change in (1)
Ang-1, Ang-2, Ang-2/Ang-1 ratio between 0 and 48 hours or
(2) the survival rate between patients receiving NO or N2.
Nitric Oxide Metabolic Products and Effects

Blood metHb, nitrate, nitrite, RSNO, and RNNO are NO reaction products. Before breathing NO, baseline blood metHb%
levels in the N2 and NO groups were 0.6 ± 0.1% (N = 37) and
0.6 ± 0.1% (N = 34), respectively (P = NS) (Figure 2B). In the
NO group, blood metHb% levels increased to 4.1 ± 0.4%
6
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(N = 33) at 12 hours, 3.2 ± 0.3% (N = 33) at 24 hours, 2.4 ±
0.3% (N = 33) at 48 hours, and 1.4 ± 0.4% (N = 32) at 72 hours
(P < .0001 at 12, 24, and 48 hours, and P = .03 at hour 72), when
compared with patients breathing N2, in whom levels of blood
metHb% did not change. The decrease in metHb% levels between
24 and 72 hours reﬂects the reduction or cessation of NO administration, because coma was reversed during recovery. Of note, 6
NO patients transiently developed metHb% levels ≥10%, and a
reduction of the inhaled NO dose per protocol led to a rapid decline in metHb% levels in each patient within 2 hours.
There was no difference of baseline nitrate levels in patients
treated with N2 or NO (P = NS) (Figure 2C). Nitrate levels
decreased in the N2-treated group over 48 hours, from
47.7 ± 21.1 to 29.5 ± 22.8 μM (P < .05). In contrast, nitrate levels
increased over 48 hours with NO treatment from 56.7 ± 28.2 to
94.7 ± 52.5 μM (P < .05). Plasma nitrate levels at 48 hours were
markedly greater in patients breathing NO versus N2 (P < .01).
After discontinuation of NO breathing, nitrate levels returned
to baseline by 120 hours. Nitrite levels (Figure 2D) did not
change signiﬁcantly from hour 0 to 48 in either group but
decreased from 48 hours to 120 hours in NO-treated patients
(P < .05). The nitrite levels in the N2- and NO-treated patients
differed at 120 hours (P < .05). Plasma RSNO and RNNO
levels were not signiﬁcantly different between the treatment
groups at hours 0, 48, and 120 of treatment (Supplementary
Table 2).

DISCUSSION
This randomized trial compared breathing 80 ppm NO versus
N2 as an in-hospital adjunctive therapy for 92 comatose pediatric patients with CM. There was no signiﬁcant difference of
plasma Ang-1, Ang-2, or cytokine levels between the groups
after 48 hours of treatment (Table 2).
Nitric oxide proved to be effective in murine CM models,
wherein PbA-infected C57BL/6 mice treated with a systemic
NO donor (dipropylenetriamine NONOate), or breathing 40
ppm NO, had improved survival [19]. Prophylactic treatment
with 80 ppm NO in the same model, with and without antimalarial therapy, resulted in a reduced mortality rate, a greater increase of plasma Ang-1 levels, reduced brain mRNA copy
numbers of the ratio of Ang-2/Ang-1, and reduced plasma levels of IFN-γ, TNF, and MCP-1 [20].
In this small clinical trial, we found an overall mortality rate
of 12%, with fewer patients dying breathing NO; however, NO
treatment did not signiﬁcantly reduce the mortality rate. The
overall mortality was less than the 18% reported in a recent multicenter study of 5425 children with severe malaria (of whom
1825 had CM) treated with IV artesunate [2]. The overall incidence rate of neurological sequelae in our study was 12%, which
is similar to the 10%–25% rate reported in sub-Saharan Africa
[3, 4]. We believe NO treatment to be safe because the mortality
rate in our study was low, breathing NO did not increase the
incidence of neurological sequelae, mean methemoglobin levels
remained low (4.1% ± 0.4%), and the number of patients affected by SAEs and AEs were similar in both groups.
Plasma S100b, a biomarker of injury to astrocytes, oligodendrocytes, and other neural cell types, is increased in patients
after traumatic brain injury and cardiac arrest [26–28]. Elevated
S100b levels have been measured in adult and pediatric CM patients with seizures, but this was only investigated using cerebrospinal ﬂuid [29, 30]. We measured plasma S100b levels in
our CM patients, and, although we found no signiﬁcant difference in the reduction of the levels between the treatment groups
over 48 hours (Table 2), plasma S100b may be useful as a tool
for assessing the level of central nervous system injury in future
studies involving CM patients.
We delivered NO or N2 with the INOPulse, a gas injector that
was triggered on inspiration. Even though it was not possible to
measure the precise NO concentration in the trachea of children
receiving NO gas with the INOPulse, we conﬁrmed that NO
was inhaled by detecting elevated levels of blood metHb%
and plasma NO metabolites (Figure 2B and C). Similar observations were reported by Gladwin et al [25], among adult sickle
cell patients breathing 40 or 80 ppm NO using the INOPulse.
We measured plasma NO metabolites in an effort to better
understand their changes in CM patients breathing NO, and
we observed increased plasma nitrate levels in the NO arm
and a reduction of nitrate levels in the N2 arm after 48 hours

of treatment (Figure 2C). After inhalation, NO has an extremely
short half-life with 97% rapidly converted to nitrate and the remainder to stable adducts (S-nitrosylated proteins [eg, S-nitrosothiols or N-nitrosamines], nitrosyl-hemeproteins, and
nitrite), which can release NO in systemic vascular beds by
various mechanisms [31, 32]. Studies have shown beneﬁcial
extrapulmonary effects of inhaled NO in humans, including reduced platelet aggregation [33], reduced myocardial injury after
cardiopulmonary bypass [34], increased renal blood ﬂow [35],
enhanced liver allograft function in liver transplant recipients
[36], and reduced inﬂammation in lower extremity ischemiareperfusion from tourniquet use [37].
Despite the possible vasodilatory and anti-inﬂammatory beneﬁts of inhaled NO described above, including the positive outcomes of NO trials in murine models of CM [11, 12], we did not
ﬁnd a signiﬁcant difference in the change of plasma Ang-1 or
Ang-2 levels after 48 hours of inhaled NO treatment. Plasma
angiopoietin levels have been correlated to the severity of illness
in severe malaria and CM patients [11, 12]. In the future, it may
be valuable to focus the administration of inhaled NO upon CM
patients with laboratory evidence of NO scavenging and pulmonary or systemic vasoconstriction. We would suggest studying
the subset of CM patients with elevated levels of plasma cellfree hemoglobin and therefore increased NO scavenging and
consumption [38]. This subset has shown evidence of increased
right heart/pulmonary pressures on echocardiogram [10]. It is
also possible that this subset of patients suffer from increased
cerebrovascular resistance with reduced cerebral blood ﬂow.
Breathing NO oxidizes cell-free hemoglobin to metHb, thereby
reducing its ability to scavenge intrinsic NO [39]. Inhaling NO
may have greater clinical efﬁcacy in this subgroup of patients.
CONCLUSIONS
Treatment with NO did not signiﬁcantly increase plasma Ang-1
levels at 48 hours compared with patients treated with N2. This
small trial could not demonstrate a reduction of mortality or
neurological impairment in children treated with NO. Seven patients in the N2 group and 4 patients in the NO group died. A
larger trial, utilizing measurements of cell-free hemoglobin and
right heart pressures to assess pulmonary vasoconstriction,
would be required to learn whether breathing NO could lead
to improved survival rates in this subgroup of malaria patients.
Supplementary Material
Supplementary material is available online at Open Forum Infectious Diseases
(http://OpenForumInfectiousDiseases.oxfordjournals.org/).
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